WO2013/019626, WO2013/019635, WO2013/019653, WO2013/019682, WO2013/036912, WO2013/041519, WO2013/042782, WO2013/045431 which are based upon other structural classes.

Summary

It is therefore the object of the present disclosure to provide compounds, which bind to the orphan nuclear receptors RORγ1 and/or RORγt and, thus, to open new methods for treating diseases associated with the modulation of RORγ, such as autoimmune diseases, inflammatory skin diseases or multiple sclerosis.

This object is solved by claims 1 to 3241.

In onethe first aspect, there is provided a compound represented by Formula (**200**) and Formula (**200'**)



(**200**) (**200'**)



(**200**) (**200'**)

an enantiomer, diastereomer, tautomer, *N*-oxide, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

R^{201} and R^{202} are independently selected from H, C_{1-10}-alkyl, C_{2-10}-alkenyl, C_{2-10}-alkynyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-(5-membered heteroaryl), C_{1-10}-alkylene-(6-membered aryl), C_{1-10}-alkylene-(6-membered heteroaryl), SO_2-C_{1-10}-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{211}, O-C_{2-6}-alkylene-OR^{211}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{211}, $CONR^{211}R^{212}$, $CONR^{211}SO_2R^{211}$, COR^{211}, SO_xR^{211}, SO_3H, $SO_2NR^{211}R^{212}$, $NR^{211}COR^{211}$, $NR^{211}SO_2R^{211}$, NR^{211}-CO-$NR^{211}R^{212}$, NR^{211}-SO_2-$NR^{211}R^{212}$, C_{3-10}-cycloalkyl, O-C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, O-C_{3-10}-heterocycloalkyl and $NR^{211}R^{212}$;

or R^{201} and R^{202} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ing is unsubstituted or substituted with 1 to 4

substituents independently selected from the group consisting of halogen, oxo, CN, OR^{211}, SO_xR^{211}, SO_3H, $NR^{211}SO_2R^{211}$, $SO_2NR^{211}R^{212}$, C_{0-6}-alkylene-CO_2R^{211}, $CONR^{211}R^{212}$, $CONR^{211}SO_2R^{211}$, COR^{211}, NR^{211}-CO-R^{211}, NR^{211}-CO-$NR^{211}R^{212}$, NR^{211}-SO_2-$NR^{211}R^{212}$, $NR^{211}R^{212}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3-8}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, COOH and oxo;

R^{203} is selected from C_{1-10}-alkyl, fluoro-C_{1-10}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-(6- to 10-membered aryl), and C_{0-6}-alkylene-(5- to 10-membered heteroaryl),

wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of oxo, halogen, CN, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, OR^{212}, CO_2R^{212}, $CONR^{212}R^{212}$ and COR^{212}; and

wherein optionally one CH_2 unit in alkyl or alkylene can be replaced by O, SO_x, NH or N(C_{1-3}-alkyl);

R^{204} is



, wherein

R^{205} and R^{206} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-8}-cycloalkyl, C_{0-6}-alkylene-C_{3-8}-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl and SO_2-C_{1-3}-alkyl, $NR^{211}R^{212}$, CO_2R^{212} and $CONR^{211}R^{212}$;

and optionally wherein R^{205} and R^{206} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of fluoro, OH, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{207} is independently selected from N and CR^{208}; or

two adjacent R^{207} form a 5- or 6-membered unsaturated or partially saturated ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, OH, oxo, C_{1-4}-alkyl and fluoro-C_{1-4}-alkyl;

R^{208} is independently selected from H, halogen, CN, C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C_{1-4}-alkylene-OH, C_{1-4}-alkylene-O-C_{1-3}-alkyl, C_{1-4}-alkylene-O-fluoro-C_{1-3}-alkyl, OH, O-C_{1-6}-alkyl, O-fluoro-C_{1-6}-alkyl and C_{3-10}-cycloalkyl,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

~~R^{209} is selected from H, halogen, CN, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;~~

R^{211} is independently selected from H, C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl and C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl,

wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, NH_2, NH(C_{1-3}-alkyl), N(C_{1-3}-alkyl)$_2$, C_{3-6}-heterocycloalkyl, C_{3-6}-cycloalkyl and SO_2-C_{1-3}-alkyl,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, CH_3 and CF_3;

R^{212} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;

~~X^{200} is selected from N and CR^{209};~~

~~Y^{200} is selected from O and S;~~

x is independently selected from 0, 1 and 2;

~~with the proviso, that 4-phenyl-5-(4-sulfamoylphenyl)oxazole-2-carboxamide is excluded.~~

~~In a second aspect, there is provided a compound represented by Formula (100) and Formula (100')~~



(100) (100')

an enantiomer, diastereomer, tautomer, *N*-oxide, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

R^{101} and R^{102} are independently selected from H, C_{1-10}-alkyl, C_{2-10}-alkenyl, C_{2-10}-alkynyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-(5-membered heteroaryl), C_{1-10}-alkylene-(6-membered aryl), C_{1-10}-alkylene-(6-membered heteroaryl), and SO_2-C_{1-10}-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{111}, O-C_{2-6}-alkylene-OR^{111}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{111}, $CONR^{111}R^{112}$, $CONR^{111}SO_2R^{111}$, COR^{111}, SO_xR^{111}, SO_3H, $SO_2NR^{111}R^{112}$, $NR^{111}COR^{111}$, $NR^{111}SO_2R^{111}$, NR^{111}-CO-$NR^{111}R^{112}$, NR^{111}-SO_2-$NR^{111}R^{112}$, C_{3-10}-cycloalkyl, O-C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, O-C_{3-10}-heterocycloalkyl and $NR^{111}R^{112}$;

or R^{101} and R^{102} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, oxo, CN, OR^{111}, SO_xR^{111}, SO_3H, $NR^{111}SO_2R^{111}$, $SO_2NR^{111}R^{112}$, C_{0-6}-alkylene-CO_2R^{111}, $CONR^{111}R^{112}$, $CONR^{111}SO_2R^{111}$, COR^{111}, NR^{111}-CO-R^{111}, NR^{111}-CO-$NR^{111}R^{112}$, NR^{111}-SO_2-$NR^{111}R^{112}$, $NR^{111}R^{112}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3-8}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consistinf of halogen, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, COOH and oxo;

R^{103} is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C_{1-6}-alkyl, C_{1-6}-alkenyl, C_{1-6}-alkynyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-(5- or 6-membered heteroaryl), C_{1-6}-alkylene-O-R^{131}, C_{0-6}-alkylene-CN, C_{0-6}-alkylene-N(R^{131})$_2$, O-C_{3-10}-cycloalkyl, O-C_{1-6}-alkylene-O-R^{131}, O-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-COOR^{131}, C_{0-6}-alkylene-C(O)R^{131}, C_{0-6}-alkylene-C(O)N(R^{131})$_2$, C_{0-6}-alkylene-N(R^{131})C(O)R^{131}, C_{0-6}-alkylene-SO-R^{131}, C_{0-6}-alkylene-SO_2-R^{131}, C_{0-6}-alkylene-SO_2-N(R^{131})$_2$, C_{0-6}-alkylene-N(R^{131})SO_2-R^{131}, C_{0-6}-alkylene-SO_2-C_{3-10}-heterocycloalkyl and C_{0-6}-alkylene-SO_2-C_{3-10}-heterocycloalkyl,

wherein alkylene, cycloalkyl, heterocycloalkyl and the 5- or 6-membered heteroaryl is optionally substituted by 1 to 4 substituents independently selected from the group consisting of halogen, CN, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, oxo, =N-OR^{132}, O-C_{1-3}-alkyl and O-halo-C_{1-3}-alkyl,

or wherein two adjacent substituents complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, oxo, =N-OR^{132}, OH, O-C_{1-6}-alkyl and O-halo-C_{1-6}-alkyl;

R^{104} is selected from (C$R^{108}$$R^{109}$)$R^{140}$, (C=O)$R^{140}$, O$R^{140}$, SO_y-R^{107} and C_{3-6}-cycloalkyl, which is spirocyclic fused with R^{140},

wherein cycloalkyl is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of F, CH_3 and CF_3;

R^{107} is selected from C_{3-10}-cycloalkyl and C_{3-10}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, cycloalkyl and heterocycloalkyl;

R^{108} is selected from H, F, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl and O-halo-C_{1-3}-alkyl;

R^{109} is selected from H, F, C_{1-3}-alkyl and halo-C_{1-3}-alkyl;

R^{111} is independently selected from H, C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl and C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl,

~~wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents selected from the group consisting of halogen, CN, OH, oxo, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, NH_2, $NH(C_{1-3}$-alkyl), $N(C_{1-3}$-alkyl)$_2$, C_{3-6}-heterocycloalkyl, C_{3-6}-cycloalkyl and SO_2-C_{1-3}-alkyl,~~

~~wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, CH_3 and CF_3;~~

~~R^{112} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;~~

~~R^{131} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-8}-cycloalkyl, C_{0-6}-alkylene-C_{3-8}-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cyclolalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, =N-OR^{132}, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl and SO_2-C_{1-3}-alkyl;~~

~~and optionally wherein two R^{131} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of fluoro, OH, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;~~

~~R^{132} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;~~

~~R^{140} is C_{3-10}-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-8}-cycloalkyl and C_{3-8}-heterocycloalkyl;~~

~~x and y are independently selected from 0, 1 and 2.~~

In a~~nother~~ ~~third~~ aspect, there is provided a compound represented by Formula (**1**) or Formula (**1'**)



an enantiomer, diastereomer, tautomer, *N*-oxide, solvate, formulation and pharmaceutically acceptable salt thereof, wherein

R^1 and R^2 are independently selected from H, C_{1-10}-alkyl, C_{2-10}-alkenyl, C_{2-10}-alkynyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-(5-membered heteroaryl) and SO_2-C_{1-10}-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{11}, O-C_{2-6}-alkylene-OR^{11}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{11}, $CONR^{11}R^{12}$, $CONR^{11}SO_2R^{11}$, COR^{11}, SO_xR^{11}, SO_3H, $SO_2NR^{11}R^{12}$, $NR^{11}COR^{11}$, $NR^{11}SO_2R^{11}$, NR^{11}-CO-$NR^{11}R^{12}$, NR^{11}-SO_2-$NR^{11}R^{12}$, C_{3-10}-cycloalkyl, O-C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, O-C_{3-10}-heterocycloalkyl and $NR^{11}R^{12}$;

or R^1 and R^2 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, oxo, CN, OR^{11}, SO_xR^{11}, SO_3H, $NR^{11}SO_2R^{11}$, $SO_2NR^{11}R^{12}$, C_{0-6}-alkylene-CO_2R^{11}, $CONR^{11}R^{12}$, $CONR^{11}SO_2R^{11}$, COR^{11}, NR^{11}-CO-R^{11}, NR^{11}-CO-$NR^{11}R^{12}$, NR^{11}-SO_2-$NR^{11}R^{12}$, $NR^{11}R^{12}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3-8}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, COOH and oxo;

R^3 is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C_{1-6}-alkyl, C_{1-6}-alkenyl, C_{1-6}-alkynyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-(5- or 6-membered heteroaryl), C_{1-6}-alkylene-O-R^{31}, C_{0-6}-alkylene-CN, C_{0-6}-alkylene-$N(R^{31})_2$, C_{0-6}-alkylene-O-C_{3-10}-cycloalkyl, O-C_{1-6}-alkylene-O-R^{31}, C_{0-6}-alkylene-O-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-$COOR^{31}$, C_{0-6}-alkylene-$C(O)R^{31}$, C_{0-6}-alkylene-$C(O)N(R^{31})_2$, C_{0-6}-alkylene-$N(R^{31})C(O)R^{31}$, C_{0-6}-alkylene-SO-R^{31}, C_{0-6}-alkylene-SO_2-R^{31}, C_{0-6}-alkylene-SO_2-$N(R^{31})_2$, C_{0-6}-alkylene-$N(R^{31})SO_2$-R^{31}, C_{0-6}-alkylene-SO_2-C_{3-10}-heterocycloalkyl and C_{0-6}-alkylene-SO_2-C_{3-10}-heterocycloalkyl,

wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and the 5- or 6-membered heteroaryl is optionally substituted by 1 to 4 substituents independently selected from the group consisting of halogen, CN, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, oxo, =N-OR^{32}, O-C_{1-6}-alkyl, O-halo-C_{1-3}-alkyl, $N(R^{31})_2$, COOH, $CON(R^{31})_2$, NR^{31}-COR^{31}, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

or wherein two adjacent substituents complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S, N, SO, SO_2 or NR^{31}, wherein the ring is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, oxo, =N-OR^{32}, OH, O-C_{1-6}-alkyl and O-halo-C_{1-6}-alkyl;

R^4 is selected from $(CR^8R^9)R^{40}$, $(C=O)R^{40}$, OR^{40}, $NR^{41}R^{40}$, SO_y-R^7 and C_{3-6}-cycloalkyl, which is spirocyclic fused with R^{40},

wherein cycloalkyl is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of F, CH_3 and CF_3;

R^7 is selected from C_{3-10}-cycloalkyl and C_{3-10}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, cycloalkyl and heterocycloalkyl;

R^8 and R^9 are independently selected from H, F, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl and O-halo-C_{1-3}-alkyl;

R^{11} is independently selected from H, C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl and C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl,

wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents selected from the group consisting of halogen, CN, OH, oxo, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, NH_2, $NH(C_{1-3}$-alkyl), $N(C_{1-3}$-alkyl$)_2$, C_{3-6}-heterocycloalkyl, C_{3-6}-cycloalkyl and SO_2-C_{1-3}-alkyl,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, CH_3 and CF_3;

R^{12} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;

R^{31} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-8}-cycloalkyl, C_{0-6}-alkylene-C_{3-8}-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, =N-OR^{32}, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl and SO_2-C_{1-3}-alkyl;

and optionally wherein two R^{31} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of fluoro, OH, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{32} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;

R^{40} is C_{3-10}-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-8}-cycloalkyl and C_{3-8}-heterocycloalkyl;

R^{41} is selected from H, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and C_{3-6}-heterocycloalkyl,

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, oxo, CN, halogen, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{3-6}-heterocycloalkyl and C_{3-6}-cycloalkyl;

x and y are independently selected from 0, 1 and 2;

W is selected from C or S=O;

with the proviso that for R^3 the 5-14 membered mono-, bi- or tricyclic heteroaryl containing ring is not



or a 5-membered aromatic heterocyclic group containing at least one oxygen atom.

In another fourth aspect, there is provided a compound according to Formula (**2**) or Formula (**2'**)



(**2**) (**2'**)



(**2**) (**2'**)

an enantiomer, diastereomer, tautomer, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

Q^1 is selected from $CO\text{-}NR^{51}R^{52}$, $CO\text{-}R^{52}$, CO_2R^{51}, $SO_2\text{-}NR^{51}R^{52}$, $SO_2\text{-}R^{52}$, $NR^{52}CO\text{-}R^{51}$ and $NR^{52}SO_2\text{-}R^{51}$;

~~Q^2 is selected from O-, S-, $CR^{55}=CR^{56}$-, N=CR^{56}-, CR^{55}=N- and N=N-;~~

~~Q^3 is selected from N and CR^{55};~~

R^{51} and R^{52} are independently selected from H, $C_{1\text{-}10}$-alkyl, $C_{2\text{-}10}$-alkenyl, $C_{2\text{-}10}$-alkynyl, $C_{0\text{-}10}$-alkylene-$C_{3\text{-}10}$-cycloalkyl, $C_{0\text{-}10}$-alkylene-$C_{3\text{-}10}$-heterocycloalkyl, $C_{0\text{-}10}$-alkylene-heteroaryl and $C_{0\text{-}10}$-alkylene-aryl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{61}, O-$C_{2\text{-}6}$-alkylene-OR^{61}, $C_{1\text{-}6}$-alkyl, halo-$C_{1\text{-}6}$-alkyl, halogen, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, SO_xR^{61}, SO_3H, $SO_2NR^{61}R^{62}$, $NR^{61}COR^{61}$, $NR^{61}SO_2R^{61}$, $NR^{61}\text{-}CO\text{-}NR^{61}R^{62}$, $NR^{61}\text{-}SO_2\text{-}NR^{61}R^{62}$, $C_{3\text{-}6}$-cycloalkyl, O-$C_{3\text{-}6}$-cycloalkyl, $C_{3\text{-}6}$-heterocycloalkyl, O-$C_{3\text{-}6}$-heterocycloalkyl and $NR^{61}R^{62}$;

or R^{51} and R^{52} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{61}, SO_xR^{61}, SO_3H, $NR^{61}SO_2R^{61}$, $SO_2NR^{61}R^{62}$, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, $NR^{61}\text{-}CO\text{-}R^{61}$, $NR^{61}\text{-}CO\text{-}NR^{61}R^{62}$, $NR^{61}\text{-}SO_2\text{-}NR^{61}R^{62}$, $NR^{61}R^{62}$, $C_{1\text{-}6}$-alkyl, halo-$C_{1\text{-}6}$-alkyl, hydroxy-$C_{1\text{-}6}$-alkyl, $C_{3\text{-}6}$-cycloalkyl, O-$C_{3\text{-}6}$-cycloalkyl, $C_{3\text{-}6}$-heterocycloalkyl and O-$C_{3\text{-}6}$-heterocycloalkyl;

R^{53} is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, $C_{1\text{-}6}$-alkyl, $C_{1\text{-}6}$-alkenyl, $C_{1\text{-}6}$-alkynyl, halo-$C_{1\text{-}6}$-alkyl, OH, O-$C_{1\text{-}6}$-alkyl, O-halo-$C_{1\text{-}6}$-alkyl, $C_{0\text{-}6}$-alkylene-$C_{3\text{-}10}$-cycloalkyl, $C_{0\text{-}6}$-alkylene-O-$C_{3\text{-}10}$-cycloalkyl, $C_{0\text{-}6}$-alkylene-$C_{3\text{-}10}$-heterocycloalkyl, $C_{0\text{-}6}$-alkylene-$COOR^{81}$, $C_{0\text{-}6}$-alkylene-$C(O)R^{81}$, $C_{0\text{-}6}$-alkylene-$C(O)N(R^{81})_2$, $C_{0\text{-}6}$-alkylene-$SO_2\text{-}N(R^{81})_2$, $C_{0\text{-}6}$-alkylene-$SO_2\text{-}R^{81}$, $C_{0\text{-}6}$-alkylene-(6-10-membered mono- or bicyclic aryl) and $C_{0\text{-}6}$-alkylene-(6-10-membered mono- or bicyclic heteroaryl),

wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, OH, oxo, =N-OR^{82}, $N(R^{81})_2$, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, COOH, $CON(R^{81})_2$, CN, NR^{81}-COR^{81}, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

or wherein two adjacent substituents may complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 members selected from O, S, SO, SO_2 or NR^{81}, wherein the ring is unsubstituted or substituted with one to four substituents independently selected from the group consisting of halogen, oxo, =N-OR^{82}, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and halo-C_{1-6}-alkyl;

R^{54} is selected from C_{1-6}-alkylene-R^{57}, ~~C_3-cycloalkyl-R^{57},~~ O-C_{0-5}-alkylene-R^{57}, ~~NR^{91}-C_{0-5}-alkylene-R^{57}~~ and SO_{2x}-~~C_{0-5}-alkylene-~~R^{57},

wherein alkylene is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, ~~OH,~~ oxo, ~~=N-OR^{82}, $N(R^{81})_2$,~~ O-C_{1-6}-alkyl, ~~COOH, $CON(R^{81})_2$,~~ CN, ~~NR^{81}-COR^{81},~~ and C_{3-6}-cycloalkyl ~~and C_{3-6}-heterocycloalkyl~~;

~~R^{55} and R^{56} are independently selected from H, halogen, CN, C_{1-6} alkyl and O-C_{1-6} alkyl,~~

~~wherein alkyl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-3}-alkyl; O-halo-C_{1-3}-alkyl and C_{3-6}-cycloalkyl;~~

R^{57} is selected from ~~C_{1-10}-alkyl,~~ C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-36}-alkyl, O-halo-C_{1-36}-alkyl, C_{1-36}-alkyl, halo-C_{1-36}-alkyl, cycloalkyl and heterocycloalkyl;

R^{61} and R^{81} independently selected from H, C_{1-6}-alkyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, phenyl, and 5-6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, phenyl, heteroaryl, halogen, NH_2, $NH(C_{1-6}$-alkyl), $N(C_{1-6}$-alkyl$)_2$, C_{3-10}-heterocycloalkyl, C_{3-10}-cycloalkyl, SO_2-C_{1-3}-alkyl, oxo and CN,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, phenyl, heteroaryl, halogen, NH_2, $NH(C_{1-6}$-alkyl), $N(C_{1-6}$-alkyl)$_2$ and C_{3-10}-cycloalkyl,

wherein phenyl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, NH_2, $NH(C_{1-6}$-alkyl), $N(C_{1-6}$-alkyl)$_2$ and C_{3-10}-cycloalkyl;

R^{62} and R^{82} are independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-10}-cycloalkyl;

R^{91} is selected from H, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and C_{3-6}-heterocycloalkyl,

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, oxo, CN, halogen, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{3-6}-heterocycloalkyl and C_{3-6}-cycloalkyl;

x is independently selected from 0, 1 and 2;

for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the RORγ receptor;

with the proviso that compounds of Formula (**2'**) with Q^1 is NHCO-R^{51}, Q^2 is sulfur, Q^3 is nitrogen, R^{53} and R^{57} are optionally substituted aryl and R^{54} is COR^{57} are excluded.

In another ~~fifth~~ aspect, there is provided a compound as defined above for use as medicament.

In another ~~sixth~~ aspect, there is provided use of a compound as defined above in the manufacture of a medicament for ~~for use in~~ the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the RORγ receptor.

In another ~~seventh~~ aspect, there is provided a pharmaceutical composition comprising a compound as defined above and a pharmaceutically acceptable carrier or excipient.

In another ~~eighth~~ aspect, there is provided use of a compound according to Formula (**2**) or Formula (**2'**)





an enantiomer, diastereomer, tautomer, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

Q^1 is selected from $CO\text{-}NR^{51}R^{52}$, $CO\text{-}R^{52}$, CO_2R^{51}, $SO_2\text{-}NR^{51}R^{52}$, $SO_2\text{-}R^{52}$, $NR^{52}CO\text{-}R^{51}$ and $NR^{52}SO_2\text{-}R^{51}$;

~~Q^2 is selected from -O-, -S-, $-CR^{55}=CR^{56}$-, $-N=CR^{56}$-, $-CR^{55}=N$- and -N=N-;~~

~~Q^3 is selected from N and CR^{55};~~

R^{51} and R^{52} are independently selected from H, $C_{1\text{-}10}$-alkyl, $C_{2\text{-}10}$-alkenyl, $C_{2\text{-}10}$-alkynyl, $C_{0\text{-}10}$-alkylene-$C_{3\text{-}10}$-cycloalkyl, $C_{0\text{-}10}$-alkylene-$C_{3\text{-}10}$-heterocycloalkyl, $C_{0\text{-}10}$-alkylene-heteroaryl and $C_{0\text{-}10}$-alkylene-aryl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{61}, O-$C_{2\text{-}6}$-alkylene-OR^{61}, $C_{1\text{-}6}$-alkyl, halo-$C_{1\text{-}6}$-alkyl, halogen, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, SO_xR^{61}, SO_3H, $SO_2NR^{61}R^{62}$, $NR^{61}COR^{61}$, $NR^{61}SO_2R^{61}$, $NR^{61}\text{-}CO\text{-}NR^{61}R^{62}$, $NR^{61}\text{-}SO_2\text{-}NR^{61}R^{62}$, $C_{3\text{-}6}$-cycloalkyl, O-$C_{3\text{-}6}$-cycloalkyl, $C_{3\text{-}6}$-heterocycloalkyl, O-$C_{3\text{-}6}$-heterocycloalkyl and $NR^{61}R^{62}$;

or R^{51} and R^{52} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{61}, SO_xR^{61}, SO_3H, $NR^{61}SO_2R^{61}$, $SO_2NR^{61}R^{62}$, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, $NR^{61}\text{-}CO\text{-}R^{61}$, $NR^{61}\text{-}CO\text{-}NR^{61}R^{62}$, $NR^{61}\text{-}SO_2\text{-}NR^{61}R^{62}$, $NR^{61}R^{62}$, $C_{1\text{-}6}$-alkyl, halo-$C_{1\text{-}6}$-alkyl, hydroxy-$C_{1\text{-}6}$-alkyl, $C_{3\text{-}6}$-cycloalkyl, O-$C_{3\text{-}6}$-cycloalkyl, $C_{3\text{-}6}$-heterocycloalkyl and O-$C_{3\text{-}6}$-heterocycloalkyl;

R^{53} is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, $C_{1\text{-}6}$-alkyl, $C_{1\text{-}6}$-alkenyl, $C_{1\text{-}6}$-alkynyl, halo-$C_{1\text{-}6}$-alkyl, OH, O-$C_{1\text{-}6}$-alkyl, O-halo-$C_{1\text{-}6}$-alkyl, $C_{0\text{-}6}$-alkylene-$C_{3\text{-}10}$-cycloalkyl, $C_{0\text{-}6}$-alkylene-O-$C_{3\text{-}10}$-cycloalkyl, $C_{0\text{-}6}$-alkylene-$C_{3\text{-}10}$-heterocycloalkyl, $C_{0\text{-}6}$-alkylene-$COOR^{81}$, $C_{0\text{-}6}$-alkylene-$C(O)R^{81}$, $C_{0\text{-}6}$-alkylene-$C(O)N(R^{81})_2$, $C_{0\text{-}6}$-alkylene-$SO_2\text{-}N(R^{81})_2$, $C_{0\text{-}6}$-alkylene-$SO_2\text{-}R^{81}$, $C_{0\text{-}6}$-alkylene-(6-10-membered mono- or bicyclic aryl) and $C_{0\text{-}6}$-alkylene-(6-10-membered mono- or bicyclic heteroaryl),

wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of $C_{1\text{-}6}$-alkyl, halo-$C_{1\text{-}6}$-alkyl, halogen, OH, oxo, =N-OR^{82}, $N(R^{81})_2$, O-$C_{1\text{-}6}$-alkyl, O-halo-$C_{1\text{-}6}$-alkyl, COOH, $CON(R^{81})_2$, CN, $NR^{81}\text{-}COR^{81}$, $C_{3\text{-}10}$-cycloalkyl, $C_{3\text{-}10}$-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

or wherein two adjacent substituents may complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 members selected from O, S, SO, SO_2 or NR^{81}, wherein the ring is unsubstituted or substituted with one to four substituents independently selected from the group consisting of halogen, oxo, =N-OR^{82}, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and halo-C_{1-6}-alkyl;

R^{54} is selected from C_{1-6}-alkylene-R^{57}, ~~C_3-cycloalkyl-R^{57}, O-C_{0-5}-alkylene-R^{57}, NR^{81}-C_{0-5}-alkylene-R^{57}~~ and SO_{2x}-C_{0-5}-alkylene-R^{57},

wherein alkylene is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, ~~OH,~~ oxo, ~~=N-OR^{82}, $N(R^{81})_2$,~~ O-C_{1-6}-alkyl, ~~COOH, $CON(R^{81})_2$,~~ CN, ~~NR^{81}-COR^{81},~~ and C_{3-6}-cycloalkyl ~~and C_{3-6}-heterocycloalkyl~~;

~~R^{55} and R^{56} are independently selected from H, halogen, CN, C_{1-6}-alkyl and O-C_{1-6}-alkyl,~~

~~wherein alkyl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-3}-alkyl; O-halo-C_{1-3}-alkyl and C_{3-6}-cycloalkyl;~~

R^{57} is selected from ~~C_{1-10}-alkyl,~~ C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-36}-alkyl, O-halo-C_{1-36}-alkyl, C_{1-36}-alkyl, halo-C_{1-36}-alkyl, cycloalkyl and heterocycloalkyl;

R^{61} and R^{81} independently selected from H, C_{1-6}-alkyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, phenyl, and 5-6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, phenyl, heteroaryl, halogen, NH_2, NH(C_{1-6}-alkyl), N(C_{1-6}-alkyl)$_2$, C_{3-10}-heterocycloalkyl, C_{3-10}-cycloalkyl, SO_2-C_{1-3}-alkyl, oxo and CN,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, phenyl, heteroaryl, halogen, NH_2, NH(C_{1-6}-alkyl), N(C_{1-6}-alkyl)$_2$ and C_{3-10}-cycloalkyl,

wherein phenyl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl,

halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, NH_2, $NH(C_{1-6}$-alkyl), $N(C_{1-6}$-alkyl$)_2$ and C_{3-10}-cycloalkyl;

R^{62} and R^{82} are independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-10}-cycloalkyl;

R^{91} is selected from H, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and C_{3-6}-heterocycloalkyl,

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, oxo, CN, halogen, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{3-6}-heterocycloalkyl and C_{3-6}-cycloalkyl;

x is independently selected from 0, 1 and 2;

in the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the RORγ receptor;

with the proviso that compounds of Formula (**2'**) with Q^1 is NHCO-R^{51}, Q^2 is sulfur, Q^3 is nitrogen, R^{53} and R^{57} are optionally substituted aryl and R^{54} is COR^{57} are excluded and wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn´s disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thromobotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.

~~In a ninth aspect, there is provided use of a compound as defined above in the manufacture of a medicament.In a tenth aspect, there is provided use of a compound as defined above in the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the RORγ receptor.~~

Thus, the present disclosure provides carboxamide or sulfonamide containing cyclic compounds as RORγ modulators, which can be used for treating or preventing a disease or disorder associated with the inactivation or activation of the RORγ receptor.

The present disclosure relates to a RORγ modulator which is based on a cyclic scaffold for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of RORγ.

When treating the disease or disorder associated with the modulation of the RORγ receptor, the activity of said receptor is preferably reduced.

Preferably, the disease or disorder is selected from the group consisting of autoimmune diseases. Autoimmune diseases comprise a group of diseases with a similar etiology of an overshooting immune response against endogenous targets resulting in chronic inflammation and physical disabilities or other severe symptoms. Autoimmune diseases comprise e.g. rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn´s disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thromobotic purpura, myasthenia gravis, Sjorgren's

Claims:

1. A compound represented by Formula (**200**) and Formula (**200'**)



(**200**)

(**200'**)



(**200**)



(**200'**)

an enantiomer, diastereomer, tautomer, *N*-oxide, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

R^{201} and R^{202} are independently selected from H, C_{1-10}-alkyl, C_{2-10}-alkenyl, C_{2-10}-alkynyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-(5-membered heteroaryl), C_{1-10}-alkylene-(6-membered aryl), C_{1-10}-alkylene-(6-membered heteroaryl), SO_2-C_{1-10}-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{211}, O-C_{2-6}-alkylene-OR^{211}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{211}, $CONR^{211}R^{212}$, $CONR^{211}SO_2R^{211}$, COR^{211}, SO_xR^{211}, SO_3H, $SO_2NR^{211}R^{212}$, $NR^{211}COR^{211}$, $NR^{211}SO_2R^{211}$, NR^{211}-CO-$NR^{211}R^{212}$, NR^{211}-SO_2-$NR^{211}R^{212}$, C_{3-10}-cycloalkyl, O-C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, O-C_{3-10}-heterocycloalkyl and $NR^{211}R^{212}$;

or R^{201} and R^{202} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{211}, SO_xR^{211}, SO_3H, $NR^{211}SO_2R^{211}$, $SO_2NR^{211}R^{212}$, C_{0-6}-alkylene-CO_2R^{211}, $CONR^{211}R^{212}$, $CONR^{211}SO_2R^{211}$, COR^{211}, NR^{211}-CO-R^{211}, NR^{211}-CO-$NR^{211}R^{212}$, NR^{211}-SO_2-$NR^{211}R^{212}$, $NR^{211}R^{212}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3-8}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, COOH and oxo;

R^{203} is selected from C_{1-10}-alkyl, fluoro-C_{1-10}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-(6- to 10-membered aryl), and C_{0-6}-alkylene-(5- to 10-membered heteroaryl),

wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of oxo, halogen, CN, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, OR^{212}, CO_2R^{212}, $CONR^{212}R^{212}$ and COR^{212}; and

wherein optionally one CH_2 unit in alkyl or alkylene can be replaced by O, SO_x, NH or $N(C_{1-3}$-alkyl);

R^{204} is



, wherein

R^{205} and R^{206} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-8}-cycloalkyl, C_{0-6}-alkylene-C_{3-8}-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl and SO_2-C_{1-3}-alkyl, $NR^{211}R^{212}$, CO_2R^{212} and $CONR^{211}R^{212}$;

and optionally wherein R^{205} and R^{206} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of fluoro, OH, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{207} is independently selected from N and CR^{208}; or

two adjacent R^{207} form a 5- or 6-membered unsaturated or partially saturated ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, OH, oxo, C_{1-4}-alkyl and fluoro-C_{1-4}-alkyl;

R^{208} is independently selected from H, halogen, CN, C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C_{1-4}-alkylene-OH, C_{1-4}-alkylene-O-C_{1-3}-alkyl, C_{1-4}-alkylene-O-fluoro-C_{1-3}-alkyl, OH, O-C_{1-6}-alkyl, O-fluoro-C_{1-6}-alkyl and C_{3-10}-cycloalkyl,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

~~R^{209} is selected from H, halogen, CN, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;~~

R^{211} is independently selected from H, C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl and C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl,

wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, NH_2, $NH(C_{1-3}$-alkyl), $N(C_{1-3}$-alkyl$)_2$, C_{3-6}-heterocycloalkyl, C_{3-6}-cycloalkyl and SO_2-C_{1-3}-alkyl,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, CH_3 and CF_3;

R^{212} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;

~~X^{200} is selected from N and CR^{209};~~

~~Y^{200} is selected from O and S;~~

x is independently selected from 0, 1 and 2;

~~with the proviso, that 4-phenyl-5-(4-sulfamoylphenyl)oxazole-2-carboxamide is excluded.~~

2. The compound according to claim 1 wherein

R^{201} is selected from H, C_{1-10}-alkyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-(5-membered heteroaryl), C_{1-10}-alkylene-(6-membered aryl), C_{1-10}-alkylene-(6-membered heteroaryl) and SO_2-C_{1-10}-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{211}, O-C_{2-6}-alkylene-OR^{211}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{211}, $CONR^{211}R^{212}$, $CONR^{211}SO_2R^{211}$, COR^{211}, SO_xR^{211}, SO_3H, $SO_2NR^{211}R^{212}$, $NR^{211}COR^{211}$, $NR^{211}SO_2R^{211}$, NR^{211}-CO-$NR^{211}R^{212}$, NR^{211}-SO_2-$NR^{211}R^{212}$, C_{3-10}-cycloalkyl, O-C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, O-C_{3-10}-heterocycloalkyl and $NR^{211}R^{212}$;

R^{202} is selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and hydroxy-C_{1-6}-alkyl;

or R^{201} and R^{202} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{211}, SO_xR^{211}, SO_3H, $NR^{211}SO_2R^{211}$, $SO_2NR^{211}R^{212}$, C_{0-6}-alkylene-CO_2R^{211}, $CONR^{211}R^{212}$, $CONR^{211}SO_2R^{211}$, COR^{211}, NR^{211}-CO-R^{211}, NR^{211}-CO-$NR^{211}R^{212}$, NR^{211}-SO_2-$NR^{211}R^{212}$, $NR^{211}R^{212}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3-8}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, COOH and oxo.



5. The compound according to any of claims 1 to 4 wherein R^{204} is selected from



wherein all R^{207} are CR^{208} or one R^{207} is N and the three other R^{207} are CR^{208}; or

wherein  is selected from



wherein the additional ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, OH, oxo, C_{1-4}-alkyl and fluoro-C_{1-4}-alkyl.

6. The compound according to any of claims 1 to 5 wherein R^{204} is selected from



wherein

R^{205} and R^{206} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-8}-cycloalkyl, C_{0-6}-alkylene-C_{3-8}-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, $NR^{211}R^{212}$, CO_2R^{212} and $CONR^{211}R^{212}$;

and optionally wherein R^{205} and R^{206} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of fluoro, OH, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl.

7. The compound according to any of claims 1 to 6 wherein $NR^{205}R^{206}$ is selected from



8. The compound according to any of claims 1 to 7 wherein

R^{203} is selected from C_{1-8}-alkyl, fluoro-C_{1-8}-alkyl, C_{0-2}-alkylene-C_{3-8}-cycloalkyl, C_{0-2}-alkylene-C_{3-8}-heterocycloalkyl, C_{0-2}-alkylene-(6- to 10-membered aryl) and C_{0-2}-alkylene-(5- to 10-membered heteroaryl),

wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of oxo, fluoro, chloro, CN, $CONH_2$, C_{1-3}-alkyl, fluoro-C_{1-3}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl and OC_{1-4}-alkyl.

9. The compound according to any of claims 1 to 7 wherein

R^{203} is selected from CHF_2, CH_2CH_3, $CH_2CH_2CH_3$, $C(CH_3)_3$, $CH_2OC(CH_3)_3$,



and .

~~10. The compound according to any of claims 1 to 9 wherein the compound is represented by a Formula selected from~~



~~and~~ ~~, wherein~~

~~R^{209} is selected from H, fluoro, chloro and methyl.~~

~~11. A compound represented by Formula (100) and Formula (100')~~



(**100**) (**100'**)

an enantiomer, diastereomer, tautomer, *N*-oxide, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

R^{101} and R^{102} are independently selected from H, C_{1-10}-alkyl, C_{2-10}-alkenyl, C_{2-10}-alkynyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-(5-membered heteroaryl), C_{1-10}-alkylene-(6-membered aryl), C_{1-10}-alkylene-(6-membered heteroaryl), and SO_2-C_{1-10}-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{111}, O-C_{2-6}-alkylene-OR^{111}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{111}, $CONR^{111}R^{112}$, $CONR^{111}SO_2R^{111}$, COR^{111}, SO_xR^{111}, SO_3H, $SO_2NR^{111}R^{112}$, $NR^{111}COR^{111}$, $NR^{111}SO_2R^{111}$, NR^{111}-CO-$NR^{111}R^{112}$, NR^{111}-SO_2-$NR^{111}R^{112}$, C_{3-10}-cycloalkyl, O-C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, O-C_{3-10}-heterocycloalkyl and $NR^{111}R^{112}$;

or R^{101} and R^{102} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, oxo, CN, OR^{111}, SO_xR^{111}, SO_3H, $NR^{111}SO_2R^{111}$, $SO_2NR^{111}R^{112}$, C_{0-6}-alkylene-CO_2R^{111}, $CONR^{111}R^{112}$, $CONR^{111}SO_2R^{111}$, COR^{111}, NR^{111}-CO-R^{111}, NR^{111}-CO-$NR^{111}R^{112}$, NR^{111}-SO_2-$NR^{111}R^{112}$, $NR^{111}R^{112}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3-8}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consistinf of halogen, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, COOH and oxo;

R^{103} is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C_{1-6}-alkyl, C_{1-6}-alkenyl, C_{1-6}-alkynyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-(5- or 6-membered heteroaryl), C_{1-6}-alkylene-O-R^{131}, C_{0-6}-alkylene-CN, C_{0-6}-alkylene-$N(R^{131})_2$, O-C_{3-10}-

cycloalkyl, O-C_{1-6}-alkylene-O-R^{131}, O-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-$COOR^{131}$, C_{0-6}-alkylene-$C(O)R^{131}$, C_{0-6}-alkylene-$C(O)N(R^{131})_2$, C_{0-6}-alkylene-$N(R^{131})C(O)R^{131}$, C_{0-6}-alkylene-SO-R^{131}, C_{0-6}-alkylene-SO_2-R^{131}, C_{0-6}-alkylene-SO_2-$N(R^{131})_2$, C_{0-6}-alkylene-$N(R^{131})SO_2$-R^{131}, C_{0-6}-alkylene-SO_2-C_{3-10}-heterocycloalkyl and C_{0-6}-alkylene-SO_2-C_{3-10}-heterocycloalkyl,

wherein alkylene, cycloalkyl, heterocycloalkyl and the 5- or 6-membered heteroaryl is optionally substituted by 1 to 4 substituents independently selected from the group consisting of halogen, CN, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, oxo, =N-OR^{132}, O-C_{1-3}-alkyl and O-halo-C_{1-3}-alkyl,

or wherein two adjacent substituents complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, oxo, =N-OR^{132}, OH, O-C_{1-6}-alkyl and O-halo-C_{1-6}-alkyl;

R^{104} is selected from $(CR^{108}R^{109})R^{140}$, $(C=O)R^{140}$, OR^{140}, SO_y-R^{107} and C_{3-6}-cycloalkyl, which is spirocyclic fused with R^{140},

wherein cycloalkyl is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of F, CH_3 and CF_3;

R^{107} is selected from C_{3-10}-cycloalkyl and C_{3-10}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, cycloalkyl and heterocycloalkyl;

R^{108} is selected from H, F, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl and O-halo-C_{1-3}-alkyl;

R^{109} is selected from H, F, C_{1-3}-alkyl and halo-C_{1-3}-alkyl;

R^{111} is independently selected from H, C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl and C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl,

wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents selected from the group consisting of halogen, CN, OH, oxo, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, NH_2, $NH(C_{1-3}$-alkyl), $N(C_{1-3}$-alkyl)$_2$, C_{3-6}-heterocycloalkyl, C_{3-6}-cycloalkyl and SO_2-C_{1-3}-alkyl,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, CH_3 and CF_3;

R^{112} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;

R^{131} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-8}-cycloalkyl, C_{0-6}-alkylene-C_{3-8}-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cyclolalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, =N-OR^{132}, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl and SO_2-C_{1-3}-alkyl;

and optionally wherein two R^{131} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of fluoro, OH, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{132} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;

R^{140} is C_{3-10}-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-8}-cycloalkyl and C_{3-8}-heterocycloalkyl;

x and y are independently selected from 0, 1 and 2.

12. The compound according to claim 11 wherein

R^{101} is selected from H, C_{1-10}-alkyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-(5-membered heteroaryl), C_{1-10}-alkylene-(6-membered aryl) and C_{1-10}-alkylene-(6-membered heteroaryl), wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{111}, O-C_{2-6}-alkylene-OR^{111}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{111}, $CONR^{111}R^{112}$, $CONR^{111}SO_2R^{111}$, COR^{111}, SO_xR^{111}, SO_3H, $SO_2NR^{111}R^{112}$, $NR^{111}COR^{111}$, $NR^{111}SO_2R^{111}$, NR^{111}-CO-$NR^{111}R^{112}$, NR^{111}-SO_2-$NR^{111}R^{112}$, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl, O-C_{3-8}-heterocycloalkyl and $NR^{111}R^{112}$;

R^{102} is selected from H, C_{1-3}-alkyl, fluoro-C_{1-3}-alkyl and hydroxy-C_{1-3}-alkyl;

or R^{101} and R^{102} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, oxo, CN, OR^{111},

SO_xR^{111}, SO_3H, $NR^{111}SO_2R^{111}$, $SO_2NR^{111}R^{112}$, C_{0-6}-alkylene-CO_2R^{111}, $CONR^{111}R^{112}$, $CONR^{111}SO_2R^{111}$, COR^{111}, NR^{111}-CO-R^{111}, NR^{111}-CO-$NR^{111}R^{112}$, NR^{111}-SO_2-$NR^{111}R^{112}$, $NR^{111}R^{112}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3-8}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, COOH and oxo.

13. The compound according to any of claims 11 to 12 wherein $NR^{101}R^{102}$ is selected from

NHMe, NHEt, $NH^{i}Pr$, $NH^{t}Bu$, $NHCH_2CONH_2$, $NHCH_2CONMe_2$, $NHCH_2CH_2OH$, $NHCH_2CH_2OMe$, $NHCH_2CH_2SO_2Me$, $NHCH_2CH_2SO_2NH_2$, $NH(CH_2)_3OH$, $NH(CH_2)_3OMe$, $NH(CH_2)_4OH$, $NH(CH_2)_4OMe$, $NH(CH_2)_5OH$, $NH(CH_2)_2CO_2H$, $NH(CH_2)_3CO_2H$, $NH(CH_2)_4CO_2H$, $NH(CH_2)_5CO_2H$, $NHCH_2CH(CF_3)OH$, $NHCH_2C(Me)(CF_3)OH$, $NHCH_2CMe_2OH$, $NHCH_2CH_2CMe_2OH$, $NHCH_2CMe_2NHCH_2CF_3$, $NHCH(Me)CMe_2OH$, $NHCH_2CMe_2OMe$, $NHCH_2CMe_2CO_2H$, $NHCH_2CMe_2CONHMe$, $NHCH_2CMe_2CONMe_2$, $NHCH_2CMe_2NHSO_2Me$, $NH(CH_2)_3SOMe$, $NH(CH_2)_5SO_2Me$, $NH(CH_2)_5SO_2NH_2$, $NH(CH_2)_3NHSO_2Me$, $NH(CH_2)_2O(CH_2)_2OH$, $NHCH_2CHMeOH$, $NH(CH_2)_5SOMe$, $NH(CH_2)_3SO_2Me$, $NHC(CH_2OH)_3$, $NHCH_2CH(OH)CH_2OH$, $N(CH_2CH_2OH)_2$,







14. The compound according to any of claims 11 to 13 wherein

R^{103} is selected from



and

wherein

R^{133} is independently selected from H, halogen, CN, C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C_{1-4}-alkylene-OH, C_{1-4}-alkylene-O-C_{1-3}-alkyl, C_{1-4}-alkylene-O-fluoro-C_{1-3}-alkyl, OH, O-C_{1-6}-alkyl, O-fluoro-C_{1-6}-alkyl, NH-C_{1-6}-alkyl, NH-fluoro-C_{1-6}-alkyl and C_{3-10}-cycloalkyl,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

R^{134} is independently selected from H, halogen, CN, C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C_{1-4}-alkylene-OH, C_{1-4}-alkylene-O-C_{1-3}-alkyl, C_{1-4}-alkylene-O-fluoro-C_{1-3}-alkyl, OH, O-C_{1-6}-alkyl, O-fluoro-C_{1-6}-alkyl, NH-C_{1-6}-alkyl, NH-fluoro-C_{1-6}-alkyl, C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, 5-membered heteroaryl, 6-membered heteroaryl, C(O)N(R^{137})$_2$ and $SO_2N(R^{137})_2$,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F and cycloalkyl, heterocycloalkyl and heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from F, C_{1-3}-alkyl, fluoro-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl and fluoro-O-C_{1-3}-alkyl;

R^{135} is selected from halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, oxo, =N-OR^{132}, OH, O-C_{1-6}-alkyl and O-halo-C_{1-6}-alkyl;

R^{136} is selected from C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C(O)N(R^{137})$_2$ and $SO_2N(R^{137})_2$;

R^{137} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{0-4}-alkylene-C_{3-6}-cycloalkyl and C_{0-4}-alkylene-C_{3-6}-heterocycloalkyl, wherein alkyl and alkylene is unsubtituted or substituted with 1 to 4 substituents selected from the group consisting of halogen, OH, O-C_{1-3}-alkyl and CN; and cycloalkyl or heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, CN, OH, oxo, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

or wherein two R^{137} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of fluoro, OH, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{138} is selected from H, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

X' is an annelated saturated heterocycle selected from the group consisting of



and

;

Y' is an annelated 5- or 6-membered carbocycle, an annelated 6-membered aryl or an annelated 6-membered heteroaryl containing 1 to 2 nitrogen atoms, wherein the carbocycle, aryl or heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of fluoro, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

Z' is an annelated 6-membered cycle forming a heteroaryl containing 1 to 2 nitrogen atoms, wherein the heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from fluoro, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

n is selected from 1 to 4.

15. The compound according to any of claims 11 to 14 wherein R^{103} is selected from







and

16. The compound according to any of claims 11 to 15 wherein

R^{104} is selected from $(CR^{108}R^{109})R^{140}$ and $(C=O)R^{140}$;

R^{108} is independently selected from H, F, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl and O-halo-C_{1-3}-alkyl;

R^{109} is selected from H, F and CH_3;

R^{140} is C_{3-10}-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, cycloalkyl and heterocycloalkyl.

17. The compound according to any of claims 11 to 16 wherein R^{104} is selected from



and

18. The compound of any of claims 11 to 17 selected from the group consisting of



~~and an enantiomer, diastereomer, tautomer, *N*-oxide, solvate and pharmaceutically acceptable salt thereof.~~

1019. A compound represented by Formula (**1**) or Formula (**1'**)



(**1**) (**1'**)

an enantiomer, diastereomer, tautomer, *N*-oxide, solvate, formulation and pharmaceutically acceptable salt thereof, wherein

R^1 and R^2 are independently selected from H, C_{1-10}-alkyl, C_{2-10}-alkenyl, C_{2-10}-alkynyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-(5-membered heteroaryl) and SO_2-C_{1-10}-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{11}, O-C_{2-6}-alkylene-OR^{11}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{11}, $CONR^{11}R^{12}$, $CONR^{11}SO_2R^{11}$, COR^{11}, SO_xR^{11}, SO_3H, $SO_2NR^{11}R^{12}$, $NR^{11}COR^{11}$, $NR^{11}SO_2R^{11}$, NR^{11}-CO-$NR^{11}R^{12}$, NR^{11}-SO_2-$NR^{11}R^{12}$, C_{3-10}-cycloalkyl, O-C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, O-C_{3-10}-heterocycloalkyl and $NR^{11}R^{12}$;

or R^1 and R^2 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{11}, SO_xR^{11}, SO_3H, $NR^{11}SO_2R^{11}$, $SO_2NR^{11}R^{12}$, C_{0-6}-alkylene-CO_2R^{11}, $CONR^{11}R^{12}$, $CONR^{11}SO_2R^{11}$, COR^{11}, NR^{11}-CO-R^{11}, NR^{11}-CO-$NR^{11}R^{12}$, NR^{11}-SO_2-$NR^{11}R^{12}$, $NR^{11}R^{12}$, C_{1-6}-alkyl, halo-C_{1-6}-

alkyl, hydroxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3-8}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substitutents independently selected from the group consisting of halogen, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, COOH and oxo;

R^3 is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C_{1-6}-alkyl, C_{1-6}-alkenyl, C_{1-6}-alkynyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-(5- or 6-membered heteroaryl), C_{1-6}-alkylene-O-R^{31}, C_{0-6}-alkylene-CN, C_{0-6}-alkylene-N(R^{31})$_2$, C_{0-6}-alkylene-O-C_{3-10}-cycloalkyl, O-C_{1-6}-alkylene-O-R^{31}, C_{0-6}-alkylene-O-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-COOR^{31}, C_{0-6}-alkylene-C(O)R^{31}, C_{0-6}-alkylene-C(O)N(R^{31})$_2$, C_{0-6}-alkylene-N(R^{31})C(O)R^{31}, C_{0-6}-alkylene-SO-R^{31}, C_{0-6}-alkylene-SO_2-R^{31}, C_{0-6}-alkylene-SO_2-N(R^{31})$_2$, C_{0-6}-alkylene-N(R^{31})SO_2-R^{31}, C_{0-6}-alkylene-SO_2-C_{3-10}-heterocycloalkyl and C_{0-6}-alkylene-SO_2-C_{3-10}-heterocycloalkyl,

wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and the 5- or 6-membered heteroaryl is optionally substituted by 1 to 4 substituents independently selected from the group consisting of halogen, CN, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, oxo, =N-OR^{32}, O-C_{1-6}-alkyl, O-halo-C_{1-3}-alkyl, N(R^{31})$_2$, COOH, CON(R^{31})$_2$, NR^{31}-COR^{31}, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

or wherein two adjacent substituents complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S, N, SO, SO_2 or NR^{31}, wherein the ring is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, oxo, =N-OR^{32}, OH, O-C_{1-6}-alkyl and O-halo-C_{1-6}-alkyl;

R^4 is selected from (CR^8R^9)R^{40}, (C=O)R^{40}, OR^{40}, N$R^{41}R^{40}$, SO_y-R^7 and C_{3-6}-cycloalkyl, which is spirocyclic fused with R^{40},

wherein cycloalkyl is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of F, CH_3 and CF_3;

R^7 is selected from C_{3-10}-cycloalkyl and C_{3-10}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, cycloalkyl and heterocycloalkyl;

R^8 and R^9 are independently selected from H, F, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl and O-halo-C_{1-3}-alkyl;

R^{11} is independently selected from H, C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl and C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl,

wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents selected from the group consisting of halogen, CN, OH, oxo, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, NH_2, NH(C_{1-3}-alkyl), N(C_{1-3}-alkyl)$_2$, C_{3-6}-heterocycloalkyl, C_{3-6}-cycloalkyl and SO_2-C_{1-3}-alkyl,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, CH_3 and CF_3;

R^{12} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;

R^{31} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-8}-cycloalkyl, C_{0-6}-alkylene-C_{3-8}-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, CN, OH, oxo, =N-OR^{32}, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl and SO_2-C_{1-3}-alkyl;

and optionally wherein two R^{31} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of fluoro, OH, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{32} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-6}-cycloalkyl;

R^{40} is C_{3-10}-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-8}-cycloalkyl and C_{3-8}-heterocycloalkyl;

R^{41} is selected from H, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and C_{3-6}-heterocycloalkyl,

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, oxo, CN, halogen, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{3-6}-heterocycloalkyl and C_{3-6}-cycloalkyl;

x and y are independently selected from 0, 1 and 2;

W is selected from C or S=O;

with the proviso that for R^3 the 5-14 membered mono-, bi- or tricyclic heteroaryl containing ring is not



or a 5-membered aromatic heterocyclic group containing at least one oxygen atom.

1120. The compound according to claim 109 wherein W is C.

1221. The compound according to any of claims 109 to 1120 wherein

R^4 is selected from $(CR^8R^9)R^{40}$, $(C=O)R^{40}$ and OR^{40};

R^8 is selected from H, F, CH_3, CF_3 and O- CH_3;

R^9 is selected from H, F and CH_3;

R^{40} is C_{3-8}-cycloalkyl, which is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of fluoro, CH_3 and CF_3.

1322. The compound according to any of claims 109 to 1221 wherein

R^1 is selected from H, C_{1-10}-alkyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, C_{1-10}-alkylene-C_{3-10}-cycloalkyl, C_{1-10}-alkylene-C_{3-10}-heterocycloalkyl and C_{1-10}-alkylene-(5-membered heteroaryl), wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{11}, O-C_{2-6}-alkylene-OR^{11}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{11}, $CONR^{11}R^{12}$, $CONR^{11}SO_2R^{11}$, COR^{11}, SO_xR^{11}, SO_3H, $SO_2NR^{11}R^{12}$, $NR^{11}COR^{11}$, $NR^{11}SO_2R^{11}$, NR^{11}-CO-$NR^{11}R^{12}$, NR^{11}-SO_2-$NR^{11}R^{12}$, C_{3-10}-cycloalkyl, O-C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, O-C_{3-10}-heterocycloalkyl and $NR^{11}R^{12}$;

R^2 is selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and hydroxy-C_{1-6}-alkyl;

or R^1 and R^2 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{11}, SO_xR^{11}, SO_3H, $NR^{11}SO_2R^{11}$, $SO_2NR^{11}R^{12}$, C_{0-6}-alkylene-CO_2R^{11}, $CONR^{11}R^{12}$, $CONR^{11}SO_2R^{11}$, COR^{11}, NR^{11}-CO-R^{11}, NR^{11}-CO-$NR^{11}R^{12}$, NR^{11}-SO_2-$NR^{11}R^{12}$, $NR^{11}R^{12}$, C_{1-6}-alkyl, halo-C_{1-6}-

alkyl, hydroxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl, O-C_{3-8}-cycloalkyl, C_{3-8}-heterocycloalkyl and O-C_{3-8}-heterocycloalkyl,

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, SO_2-C_{1-3}-alkyl, COOH and oxo.

~~1423~~. The compound according to any of claims 1~~09~~ to 1~~322~~ wherein NR^1R^2 is selected from

NHMe, NHEt, NH^{i}Pr, NH^{t}Bu, $NHCH_2CONH_2$, $NHCH_2CONMe_2$, $NHCH_2CH_2OH$, $NHCH_2CH_2OMe$, $NHCH_2CH_2SO_2Me$, $NHCH_2CH_2SO_2NH_2$, $NH(CH_2)_3OH$, $NH(CH_2)_3OMe$, $NH(CH_2)_4OH$, $NH(CH_2)_4OMe$, $NH(CH_2)_5OH$, $NH(CH_2)_2CO_2H$, $NH(CH_2)_3CO_2H$, $NH(CH_2)_4CO_2H$, $NH(CH_2)_5CO_2H$, $NHCH_2CH(CF_3)OH$, $NHCH_2C(Me)(CF_3)OH$, $NHCH_2CMe_2OH$, $NHCH_2CH_2CMe_2OH$, $NHCH_2CMe_2NHCH_2CF_3$, $NHCH(Me)CMe_2OH$, $NHCH_2CMe_2OMe$, $NHCH_2CMe_2CO_2H$, $NHCH_2CMe_2CONHMe$, $NHCH_2CMe_2CONMe_2$, $NHCH_2CMe_2NHSO_2Me$, $NH(CH_2)_3SOMe$, $NH(CH_2)_5SO_2Me$, $NH(CH_2)_5SO_2NH_2$, $NH(CH_2)_3NHSO_2Me$, $NH(CH_2)_2O(CH_2)_2OH$, $NHCH_2CHMeOH$, $NH(CH_2)_5SOMe$, $NH(CH_2)_3SO_2Me$, $NHC(CH_2OH)_3$, $NHCH_2CH(OH)CH_2OH$, $N(CH_2CH_2OH)_2$,







and

.

1524. The compound according to any of claims 1~~09~~ to 1~~423~~ wherein

R^3 is a 6-10 membered mono- or bicyclic aryl or a 5-10 membered mono- or bicyclic heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S

wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-O-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-$COOR^{31}$, C_{0-6}-alkylene-$C(O)R^{31}$, C_{0-6}-alkylene-$C(O)N(R^{31})_2$, C_{0-6}-alkylene-SO_2-$N(R^{31})_2$, C_{0-6}-alkylene-SO_2-R^{31}, C_{0-6}-alkylene-(5-membered heteroaryl), C_{0-6}-alkylene-(6-membered heteroaryl),

wherein alkyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, =N-OR^{32}, $N(R^{31})_2$, O-C_{1-6}-alkyl; COOH, $CON(R^{31})_2$, CN, NR^{31}-COR^{31}, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

or wherein two adjacent substituents may complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 members selected from O, S, SO, SO_2 or NR^{31}, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from halogen, oxo, =N-OR^{32}, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and halo-C_{1-6}-alkyl.

1625. The compound according to any of claim 109 to 1524 wherein R^3 is selected from



wherein

R^{33} is independently selected from H, halogen, CN, C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C_{1-4}-alkylene-OH, C_{1-4}-alkylene-O-C_{1-3}-alkyl, C_{1-4}-alkylene-O-fluoro-C_{1-3}-alkyl, OH, O-C_{1-6}-alkyl, O-fluoro-C_{1-6}-alkyl, NH-C_{1-6}-alkyl, NH-fluoro-C_{1-6}-alkyl, C_{3-10}-cycloalkyl,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

R^{34} are independently selected from H, halogen, CN, C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C_{1-4}-alkylene-OH, C_{1-4}-alkylene-O-C_{1-3}-alkyl, C_{1-4}-alkylene-O-fluoro-C_{1-3}-alkyl, OH, O-C_{1-6}-alkyl, O-fluoro-C_{1-6}-alkyl, NH-C_{1-6}-alkyl, NH-fluoro-C_{1-6}-alkyl, C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, 5-membered heteroaryl, 6-membered heteroaryl, $C(O)N(R^{37})_2$ and $SO_2N(R^{37})_2$,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F and cycloalkyl, heterocycloalkyl and heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from F, C_{1-3}-alkyl, fluoro-C_{1-3}-alkyl, OH, O-C_{1-3}-alkyl, fluoro-O-C_{1-3}-alkyl;

R^{35} is selected from halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, oxo, OH, O-C_{1-6}-alkyl and O-halo-C_{1-6}-alkyl;

R^{36} is selected from C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, $C(O)N(R^{37})_2$, $SO_2N(R^{37})_2$;

R^{37} is independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, C_{0-4}-alkylene-C_{3-6}-cycloalkyl, C_{0-4}-alkylene-C_{3-6}-heterocycloalkyl, wherein alkyl and alkylene is unsubstituted or substituted with 1 to 4 substituents selected from halogen, OH, O-C_{1-3}-alkyl, CN, $CONH_2$; and cycloalkyl or heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from F, CN, OH, oxo, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

or wherein two R^{37} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from fluoro, OH, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{38} is selected from H, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

X is an annelated saturated heterocycle selected from the group consisting of



;

Y is an annelated 5- or 6-membered carbocycle, an annelated 6-membered aryl or an annelated 6-membered heteroaryl containing 1 to 2 nitrogen atoms, wherein the carbocycle, aryl or heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from halogen, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

Z is an annelated 6-membered cycle forming a heteroaryl containing 1 to 2 nitrogen atoms, wherein the heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from fluoro, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

n is selected from 1 to 4.

17~~26~~. The compound according to any of claims 1~~09~~ to 16~~25~~ wherein R^3 is selected from







and

1827. The compound according to any of claims 109 to 1726 represented by Formula (**1**).

1928. The compound according to any of claims 109 to 1827, wherein the compound is selected from




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



and an enantiomer, diastereomer, tautomer, *N*-oxide, solvate and pharmaceutically acceptable salt thereof.

209. A compound according to Formula (**2**) or Formula (**2'**)



an enantiomer, diastereomer, tautomer, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

Q^1 is selected from CO-$NR^{51}R^{52}$, CO-R^{52}, CO_2R^{51}, SO_2-$NR^{51}R^{52}$, SO_2-R^{52}, $NR^{52}CO$-R^{51} and $NR^{52}SO_2$-R^{51};

~~Q^2 is selected from O, S, $CR^{55}=CR^{56}$, $N=CR^{56}$, $CR^{55}=N$ and N=N;~~

~~Q^3 is selected from N and CR^{55};~~

R^{51} and R^{52} are independently selected from H, C_{1-10}-alkyl, C_{2-10}-alkenyl, C_{2-10}-alkynyl, C_{0-10}-alkylene-C_{3-10}-cycloalkyl, C_{0-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-10}-alkylene-heteroaryl and C_{0-10}-alkylene-aryl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR^{61}, O-C_{2-6}-alkylene-OR^{61}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, SO_xR^{61}, SO_3H, $SO_2NR^{61}R^{62}$,

$NR^{61}COR^{61}$, $NR^{61}SO_2R^{61}$, NR^{61}-CO-$NR^{61}R^{62}$, NR^{61}-SO_2-$NR^{61}R^{62}$, C_{3-6}-cycloalkyl, O-C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, O-C_{3-6}-heterocycloalkyl and $NR^{61}R^{62}$;

or R^{51} and R^{52} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{61}, SO_xR^{61}, SO_3H, $NR^{61}SO_2R^{61}$, $SO_2NR^{61}R^{62}$, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, NR^{61}-CO-R^{61}, NR^{61}-CO-$NR^{61}R^{62}$, NR^{61}-SO_2-$NR^{61}R^{62}$, $NR^{61}R^{62}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, O-C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl and O-C_{3-6}-heterocycloalkyl;

R^{53} is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, C_{1-6}-alkyl, C_{1-6}-alkenyl, C_{1-6}-alkynyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-O-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-$COOR^{81}$, C_{0-6}-alkylene-$C(O)R^{81}$, C_{0-6}-alkylene-$C(O)N(R^{81})_2$, C_{0-6}-alkylene-SO_2-$N(R^{81})_2$, C_{0-6}-alkylene-SO_2-R^{81}, C_{0-6}-alkylene-(6-10-membered mono- or bicyclic aryl) and C_{0-6}-alkylene-(6-10-membered mono- or bicyclic heteroaryl),

wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, OH, oxo, =N-OR^{82}, $N(R^{81})_2$, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, COOH, $CON(R^{81})_2$, CN, NR^{81}-COR^{81}, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

or wherein two adjacent substituents may complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 members selected from O, S, SO, SO_2 or NR^{81}, wherein the ring is unsubstituted or substituted with one to four substituents independently selected from the group consisting of halogen, oxo, =N-OR^{82}, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and halo-C_{1-6}-alkyl;

R^{54} is selected from ~~C_0~~C_{1-6}-alkylene-R^{57}, ~~C_3-cycloalkyl-R^{57}~~, ~~O-~~C_{0-5}-alkylene-R^{57}, ~~NR^{91}-C_{0-5}-alkylene-R^{57}~~ and ~~SO_{2x}-~~C_{0-5}-alkylene-R^{57},

wherein alkylene is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, ~~OH,~~ oxo, ~~=N-OR^{82}, $N(R^{81})_2$,~~ O-C_{1-6}-alkyl, ~~COOH, $CON(R^{81})_2$,~~ CN, ~~NR^{81}-COR^{81},~~ and C_{3-6}-cycloalkyl ~~and C_{3-6}-heterocycloalkyl~~;

~~R^{55} and R^{56} are independently selected from H, halogen, CN, C_{1-6}-alkyl and O-C_{1-6}-alkyl,~~

~~wherein alkyl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-3}-alkyl; O-halo-C_{1-3}-alkyl and C_{3-6}-cycloalkyl;~~

R^{57} is selected from ~~C_{1-10}-alkyl,~~ C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-36}-alkyl, O-halo-C_{1-36}-alkyl, C_{1-36}-alkyl, halo-C_{1-36}-alkyl, cycloalkyl and heterocycloalkyl;

R^{61} and R^{81} independently selected from H, C_{1-6}-alkyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, phenyl, and 5-6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, phenyl, heteroaryl, halogen, NH_2, NH(C_{1-6}-alkyl), N(C_{1-6}-alkyl)$_2$, C_{3-10}-heterocycloalkyl, C_{3-10}-cycloalkyl, SO_2-C_{1-3}-alkyl, oxo and CN,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, phenyl, heteroaryl, halogen, NH_2, NH(C_{1-6}-alkyl), N(C_{1-6}- alkyl)$_2$ and C_{3-10}-cycloalkyl,

wherein phenyl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, NH_2, NH(C_{1-6}-alkyl), N(C_{1-6}-alkyl)$_2$ and C_{3-10}-cycloalkyl;

R^{62} and R^{82} are independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-10}-cycloalkyl;

R^{91} is selected from H, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and C_{3-6}-heterocycloalkyl,

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, oxo, CN, halogen, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{3-6}-heterocycloalkyl and C_{3-6}-cycloalkyl;

x is independently selected from 0, 1 and 2;

for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the RORγ receptor;

with the proviso that compounds of Formula (**2'**) with Q^1 is NHCO-R^{51}, Q^2 is sulfur, Q^3 is nitrogen, R^{53} and R^{57} are optionally substituted aryl and R^{54} is COR^{57} are excluded.

2130. The compound for use according to claim 209 wherein

Q^1 is selected from $CO\text{-}NR^{51}R^{52}$ and $NR^{52}CO\text{-}R^{51}$;

~~Q^2 is selected from -O- and -S-; and~~

~~Q^3 is N.~~

2231. The compound for use according to any of claims 2029 to 2130 wherein

R^{51} is selected from H, $C_{1\text{-}10}$-alkyl, $C_{0\text{-}10}$-alkylene-$C_{3\text{-}10}$-cycloalkyl, and $C_{0\text{-}10}$-alkylene-$C_{3\text{-}10}$-heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, OR^{61}, $C_{1\text{-}6}$-alkyl, halo-$C_{1\text{-}6}$-alkyl, halogen, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, $NR^{61}COR^{61}$, $NR^{61}SO_2R^{61}$, $NR^{61}\text{-}CO\text{-}NR^{61}R^{62}$, $NR^{61}\text{-}SO_2\text{-}NR^{61}R^{62}$, $C_{3\text{-}6}$-cycloalkyl, O-$C_{3\text{-}6}$-cycloalkyl, $C_{3\text{-}6}$-heterocycloalkyl and O-$C_{3\text{-}6}$-heterocycloalkyl;

R^{52} is selected from the group consisting of H, $C_{1\text{-}6}$ alkyl and halo-$C_{1\text{-}6}$ alkyl;

or R^{51} and R^{52} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{61}, SO_xR^{61}, SO_3H, $NR^{61}SO_2R^{61}$, $SO_2NR^{61}R^{62}$, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, $NR^{61}\text{-}CO\text{-}R^{61}$, $NR^{61}\text{-}CO\text{-}NR^{61}R^{62}$, $NR^{61}\text{-}SO_2\text{-}NR^{61}R^{62}$, $NR^{61}R^{62}$, $C_{1\text{-}6}$-alkyl, halo-$C_{1\text{-}6}$-alkyl, hydroxy-$C_{1\text{-}6}$-alkyl, $C_{3\text{-}6}$-cycloalkyl, O-$C_{3\text{-}6}$-cycloalkyl, $C_{3\text{-}6}$-heterocycloalkyl and O-$C_{3\text{-}6}$-heterocycloalkyl.

2332. The compound for use according to any of claims 2029 to 2231 wherein R^{53} is selected from



and ,

wherein

R^{83} is selected from halogen, $C_{1\text{-}6}$-alkyl, fluoro-$C_{1\text{-}6}$-alkyl, $C_{1\text{-}4}$-alkylene-OH, $C_{1\text{-}4}$-alkylene-CN, $C_{1\text{-}4}$-alkylene-O-$C_{1\text{-}3}$-alkyl, $C_{1\text{-}4}$-alkylene-O-fluoro-$C_{1\text{-}3}$-alkyl, O-$C_{1\text{-}6}$-alkyl, O-fluoro-$C_{1\text{-}6}$-alkyl, $C_{3\text{-}10}$-cycloalkyl, $C(O)N(R^{87})_2$,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F, and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

R^{84} is selected from C_{1-4}-alkylene-OH, C_{1-4}-alkylene-O-C_{1-3}-alkyl, C_{1-4}-alkylene-O-fluoro-C_{1-3}-alkyl, C_{3-10}-cycloalkyl, $C(O)N(R^{87})_2$ and $S(O_2)N(R^{87})_2$,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F, and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

R^{86} is selected from C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, $C(O)N(R^{87})_2$ and $S(O_2)N(R^{87})_2$,

R^{87} is independently selected from H, C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C_{0-3}-alkylene-C_{1-6}-cycloalkyl, C_{1-6}-alkylene-OH, C_{1-6}-alkylene-O-C_{1-3}-alkyl and C_{1-6}-alkylene-CN, wherein alkylene and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl,

and wherein two R^{87} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of fluoro, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{88} is selected from H, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

R^{89} is selected from H, F or OH;

X' is an annelated saturated heterocycle selected from the group consisting of



and  ;

Y' is an annelated 5- or 6-membered carbocycle, an annelated 6-membered aryl or an annelated 6-membered heteroaryl containing 1 to 2 nitrogen atoms, wherein the carbocycle, aryl or heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of fluoro, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

Z' is an annelated 6-membered cycle forming a heteroaryl containing 1 to 2 nitrogen atoms, wherein the heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of fluoro, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl; and

m is selected from 1 to 4.

~~33. The compound for use according to any of claims 29 to 32 wherein~~

~~R^{54} is selected from C_{1-6}-alkylene-R^{57}, O-R^{57} and SO_2-R^{57};~~

~~wherein alkylene is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, CN and C_{3-6}-cycloalkyl;~~

~~R^{57} is selected from C_{1-10}-alkyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,~~

~~wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, cycloalkyl and heterocycloalkyl.~~

24~~34~~. The compound according to any of claims 1 to 19~~28~~ for use as medicament.

23~~5~~. Use of t~~T~~he compound according to any of claims 1 to 19~~28~~ ~~for use~~ in the manufacture of a medicament for~~in~~ the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the RORγ receptor.

26~~36~~. The ~~compound for~~ use according to claim 25~~35~~, wherein the disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn´s disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thromobotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.

27~~37~~. A pharmaceutical composition comprising a compound according to any of claims 1 to 23~~33~~ and a pharmaceutically acceptable carrier or excipient.

28~~38~~. The compound for use according to any of claims 2~~09~~ to 2~~3~~3, wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel

diseases such as Crohn´s disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thromobotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.

~~2939~~. Use of a compound according to Formula (2) or Formula (2')



an enantiomer, diastereomer, tautomer, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

Q^1 is selected from CO-$NR^{51}R^{52}$, CO-R^{52}, CO_2R^{51}, SO_2-$NR^{51}R^{52}$, SO_2-R^{52}, $NR^{52}CO$-R^{51} and $NR^{52}SO_2$-R^{51};

~~Q^2 is selected from O, S, $CR^{55}=CR^{56}$, $N=CR^{56}$, $CR^{55}=N$ and N=N;~~

~~Q^3 is selected from N and CR^{55};~~

R^{51} and R^{52} are independently selected from H, C_{1-10}-alkyl, C_{2-10}-alkenyl, C_{2-10}-alkynyl, C_{0-10}-alkylene-C_{3-10}-cycloalkyl, C_{0-10}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-10}-alkylene-heteroaryl and C_{0-10}-alkylene-aryl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR_{61}, O-C_{2-6}-alkylene-OR_{61}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, SO_xR^{61}, SO_3H, $SO_2NR^{61}R^{62}$, $NR^{61}COR^{61}$, $NR^{61}SO_2R^{61}$, NR^{61}-CO-$NR^{61}R^{62}$, NR^{61}-SO_2-$NR^{61}R^{62}$, C_{3-6}-cycloalkyl, O-C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl, O-C_{3-6}-heterocycloalkyl and $NR^{61}R^{62}$;

or R^{51} and R^{52} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{61}, SO_xR^{61}, SO_3H, $NR^{61}SO_2R^{61}$, $SO_2NR^{61}R^{62}$, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, NR^{61}-CO-R^{61}, NR^{61}-CO-$NR^{61}R^{62}$, NR^{61}-SO_2-$NR^{61}R^{62}$, $NR^{61}R^{62}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, O-C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl and O-C_{3-6}-heterocycloalkyl;

R^{53} is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S,

wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, C_{1-6}-alkyl, C_{1-6}-alkenyl, C_{1-6}-alkynyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{0-6}-alkylene-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-O-C_{3-10}-cycloalkyl, C_{0-6}-alkylene-C_{3-10}-heterocycloalkyl, C_{0-6}-alkylene-$COOR^{81}$, C_{0-6}-alkylene-$C(O)R^{81}$, C_{0-6}-alkylene-$C(O)N(R^{81})_2$, C_{0-6}-alkylene-SO_2-$N(R^{81})_2$, C_{0-6}-alkylene-SO_2-R^{81}, C_{0-6}-alkylene-(6-10-membered mono- or bicyclic aryl) and C_{0-6}-alkylene-(6-10-membered mono- or bicyclic heteroaryl),

wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, OH, oxo, =N-OR^{82}, $N(R^{81})_2$, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, COOH, $CON(R^{81})_2$, CN, NR^{81}-COR^{81}, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

or wherein two adjacent substituents may complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 members selected from O, S, SO, SO_2 or NR^{81}, wherein the ring is unsubstituted or substituted with one to four substituents independently selected from the group consisting of halogen, oxo, =N-OR^{82}, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and halo-C_{1-6}-alkyl;

R^{54} is selected from C_{1-6}-alkylene-R^{57}, ~~C_3-cycloalkyl-R^{57}~~, O-~~C_{0-5}-alkylene-R^{57}~~, ~~NR^{81}-C_{0-5}-alkylene-R^{57}~~ and SO_{2x}-~~C_{0-5}-alkylene-~~R^{57},

wherein alkylene is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, ~~OH~~, oxo, ~~=N-OR^{82}, $N(R^{81})_2$~~, O-C_{1-6}-alkyl, ~~COOH, $CON(R^{81})_2$~~, CN, ~~NR^{81}-COR^{81}~~, and C_{3-6}-cycloalkyl ~~and C_{3-6}-heterocycloalkyl~~;

~~R^{55} and R^{56} are independently selected from H, halogen, CN, C_{1-6}-alkyl and O-C_{1-6}-alkyl,~~

~~wherein alkyl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl and C_{3-6}-cycloalkyl;~~

R^{57} is selected from ~~C_{1-10}-alkyl,~~ C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of

halogen, OH, oxo, O-C_{1-6}-alkyl, O-halo-C_{1-36}-alkyl, C_{1-36}-alkyl, halo-C_{1-36}-alkyl, cycloalkyl and heterocycloalkyl;

R^{61} and R^{81} independently selected from H, C_{1-6}-alkyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, phenyl, and 5-6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, phenyl, heteroaryl, halogen, NH_2, NH(C_{1-6}-alkyl), N(C_{1-6}-alkyl)$_2$, C_{3-10}-heterocycloalkyl, C_{3-10}-cycloalkyl, SO_2-C_{1-3}-alkyl, oxo and CN,

wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C_{1-6}-alkyl, halo-C_{1-6}-alkyl, OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, phenyl, heteroaryl, halogen, NH_2, NH(C_{1-6}-alkyl), N(C_{1-6}-alkyl)$_2$ and C_{3-10}-cycloalkyl,

wherein phenyl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, halogen, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, NH_2, NH(C_{1-6}-alkyl), N(C_{1-6}-alkyl)$_2$ and C_{3-10}-cycloalkyl;

R^{62} and R^{82} are independently selected from H, C_{1-6}-alkyl, halo-C_{1-6}-alkyl and C_{3-10}-cycloalkyl;

R^{91} is selected from H, C_{1-6}-alkyl, C_{3-6}-cycloalkyl and C_{3-6}-heterocycloalkyl,

wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, oxo, CN, halogen, O-C_{1-6}-alkyl, O-halo-C_{1-6}-alkyl, C_{3-6}-heterocycloalkyl and C_{3-6}-cycloalkyl;

x is independently selected from 0, 1 and 2;

in the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the RORγ receptor;

with the proviso that compounds of Formula (2') with Q^1 is NHCO-R^{51}, Q^2 is sulfur, Q^3 is nitrogen, R^{53} and R^{57} are optionally substituted aryl and R^{54} is COR^{57} are excluded and wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn´s disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thromobotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.

3040. The use according to claim 2939 wherein

Q^1 is selected from CO-$NR^{51}R^{52}$ and NR^{52}CO-R^{51};

~~Q^2 is selected from -O- and -S-; and~~

~~Q^3 is N.~~

3141. The use according to any of claims 2939 to 3040 wherein

R^{51} is selected from H, C_{1-10}-alkyl, C_{0-10}-alkylene-C_{3-10}-cycloalkyl, and C_{0-10}-alkylene-C_{3-10}-heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, OR^{61}, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, halogen, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, $NR^{61}COR^{61}$, $NR^{61}SO_2R^{61}$, NR^{61}-CO-$NR^{61}R^{62}$, NR^{61}-SO_2-$NR^{61}R^{62}$, C_{3-6}-cycloalkyl, O-C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl and O-C_{3-6}-heterocycloalkyl;

R^{52} is selected from the group consisting of H, C_{1-6} alkyl and halo-C_{1-6} alkyl;

or R^{51} and R^{52} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR^{61}, SO_xR^{61}, SO_3H, $NR^{61}SO_2R^{61}$, $SO_2NR^{61}R^{62}$, CO_2R^{61}, $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61}, NR^{61}-CO-R^{61}, NR^{61}-CO-$NR^{61}R^{62}$, NR^{61}-SO_2-$NR^{61}R^{62}$, $NR^{61}R^{62}$, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{3-6}-cycloalkyl, O-C_{3-6}-cycloalkyl, C_{3-6}-heterocycloalkyl and O-C_{3-6}-heterocycloalkyl.

3242. The use according to any of claims ~~2939~~ to ~~3144~~ wherein R^{53} is selected from



and

wherein

R^{83} is selected from halogen, C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C_{1-4}-alkylene-OH, C_{1-4}-alkylene-CN, C_{1-4}-alkylene-O-C_{1-3}-alkyl, C_{1-4}-alkylene-O-fluoro-C_{1-3}-alkyl, O-C_{1-6}-alkyl, O-fluoro-C_{1-6}-alkyl, C_{3-10}-cycloalkyl, $C(O)N(R^{87})_2$,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F, and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

R^{84} is selected from C_{1-4}-alkylene-OH, C_{1-4}-alkylene-O-C_{1-3}-alkyl, C_{1-4}-alkylene-O-fluoro-C_{1-3}-alkyl, C_{3-10}-cycloalkyl, $C(O)N(R^{87})_2$ and $S(O_2)N(R^{87})_2$,

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F, and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

R^{86} is selected from C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, $C(O)N(R^{87})_2$ and $S(O_2)N(R^{87})_2$,

R^{87} is independently selected from H, C_{1-6}-alkyl, fluoro-C_{1-6}-alkyl, C_{0-3}-alkylene-C_{1-6}-cycloalkyl, C_{1-6}-alkylene-OH, C_{1-6}-alkylene-O-C_{1-3}-alkyl and C_{1-6}-alkylene-CN, wherein alkylene and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl,

and wherein two R^{87} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of fluoro, oxo, C_{1-4}-alkyl and halo-C_{1-4}-alkyl;

R^{88} is selected from H, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

R^{89} is selected from H, F or OH;

X' is an annelated saturated heterocycle selected from the group consisting of



and ;

Y' is an annelated 5- or 6-membered carbocycle, an annelated 6-membered aryl or an annelated 6-membered heteroaryl containing 1 to 2 nitrogen atoms, wherein the carbocycle, aryl or heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of fluoro, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl;

Z' is an annelated 6-membered cycle forming a heteroaryl containing 1 to 2 nitrogen atoms, wherein the heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of fluoro, C_{1-3}-alkyl and fluoro-C_{1-3}-alkyl; and

m is selected from 1 to 4.

43. The use according to any of claims 39 to 42 wherein

R^{54} is selected from C_{1-6}-alkylene-R^{57}, O-R^{57} and SO_2-R^{57};

wherein alkylene is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-6}-alkyl, CN and C_{3-6}-cycloalkyl;

R^{57} is selected from C_{1-10}-alkyl, C_{3-10}-cycloalkyl, C_{3-10}-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl,

wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C_{1-3}-alkyl, O-halo-C_{1-3}-alkyl, C_{1-3}-alkyl, halo-C_{1-3}-alkyl, cycloalkyl and heterocycloalkyl.

44. Use of a compound according to any of claims 1 to 28 in the manufacture of a medicament.

45. Use of a compound according to any of claims 1 to 28 in the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the RORγ receptor.

46. The use of a compound according to claim 45, wherein the disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn´s disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thromobotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.